Article
EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients.
Thoracic cancer - 1 Oct 2020
Leal Leticia F, Laus Ana C, Cavagna Rodrigo, de Paula Flavia E, de Oliveira Marco A, Ribeiro Dayana M, Hassan Fernanda M, Miziara José E, da Silva Eduardo C Albino, da Silva Vinicius D, De Marchi Pedro, Reis Rui M
Abstract excerpt
Epidermal growth factor (EGF) and its receptor (EGFR) play a paramount role in lung carcinogenesis. The polymorphism in the EGF promoter region EGF+61A>G (rs4444903) has been associated with cancer susceptibility, but its role in lung cancer patients treated with tyrosine kinase inhibitors (TKIs) remains unknown. Here, we aimed to evaluate the predictive and prognostic role of EGF+61A>G SNP in lung cancer from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.